pubmed.ncbi.nlm.nih.gov

Viral vectors in malaria vaccine development - PubMed

Review

Viral vectors in malaria vaccine development

K J Limbach et al. Parasite Immunol. 2009 Sep.

Abstract

Traditional vaccine technologies have resulted in an impressive array of efficacious vaccines against a variety of infectious agents. However, several potentially deadly pathogens, including retroviruses and parasites, have proven less amenable to the application of traditional vaccine platforms, indicating the need for new approaches. Viral vectors represent an attractive way to deliver and present vaccine antigens that may offer advantages over traditional platforms. Due to their ability to induce strong cell-mediated immunity (CMI) in addition to antibodies, viral vectors may be suitable for infectious agents, such as malaria parasites, where potent CMI is required for protection. Poxvirus-vectored malaria vaccines have been the most extensively studied in the clinic, achieving significant reductions in liver-stage parasite burden. More recently, adenovirus-vectored malaria vaccines have entered clinical testing. The most promising approach - heterologous prime-boost regimens, in which different viral vectors are sequentially paired with each other or with DNA or recombinant protein vaccines - is now being explored, and could provide high-grade protection, if findings in animal models are translatable to humans. Significant barriers remain, however, such as pre-existing immunity to the vector particle and an unexplained safety signal observed in one trial suggesting an increased risk of HIV acquisition in volunteers with pre-existing immunity to the vector.

PubMed Disclaimer

Cited by

An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.
Zhou D, Zhou X, Bian A, Li H, Chen H, Small JC, Li Y, Giles-Davis W, Xiang Z, Ertl HCJ. Zhou D, et al. Nat Protoc. 2010 Nov;5(11):1775-1785. doi: 10.1038/nprot.2010.134. Epub 2010 Oct 14. Nat Protoc. 2010. PMID: 21030953 Free PMC article.
Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors.
Cottingham MG, Carroll F, Morris SJ, Turner AV, Vaughan AM, Kapulu MC, Colloca S, Siani L, Gilbert SC, Hill AV. Cottingham MG, et al. Biotechnol Bioeng. 2012 Mar;109(3):719-28. doi: 10.1002/bit.24342. Epub 2011 Nov 6. Biotechnol Bioeng. 2012. PMID: 22252512 Free PMC article.
Recombinant vaccines and the development of new vaccine strategies.
Nascimento IP, Leite LC. Nascimento IP, et al. Braz J Med Biol Res. 2012 Dec;45(12):1102-11. doi: 10.1590/s0100-879x2012007500142. Epub 2012 Sep 6. Braz J Med Biol Res. 2012. PMID: 22948379 Free PMC article.
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.
Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Manohar N, Richie NO, Wood C, Long CA, Regis D, Williams FT, Shi M, Chuang I, Spring M, Epstein JE, Mendoza-Silveiras J, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Soisson L, Diggs C, Carucci D, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL. Sedegah M, et al. PLoS One. 2011;6(10):e24586. doi: 10.1371/journal.pone.0024586. Epub 2011 Oct 7. PLoS One. 2011. PMID: 22003383 Free PMC article. Clinical Trial.
CD8⁺ T Cell Responses to Plasmodium and Intracellular Parasites.
Villarino N, Schmidt NW. Villarino N, et al. Curr Immunol Rev. 2013 Aug;9(3):169-178. doi: 10.2174/1573395509666131126232327. Curr Immunol Rev. 2013. PMID: 24741372 Free PMC article.

Viral vectors in malaria vaccine development - PubMed